Paratek Pharmaceuticals Inc. said it has delivered the first procurement of Nuzyra to the Biomedical Advanced Research and Development Authority, part of the U.S. Department of Health and Human Services, and BARDA has taken title of the product.
Th biopharmaceutical company said this procurement is valued at about $38 million and will be recognized in its second quarter net sales of Nuzyra.
In December 2019, BARDA awarded Paratek a five-year contract, valued at up to $284.5 million, to support the development of Nuzyra for the treatment of pulmonary anthrax; U.S. Food and Drug Administration post-marketing requirements associated with the initial Nuzyra approval; U.S. onshoring of Nuzyra and manufacturing security requirements; and up to four procurements of Nuzyra.
This Project BioShield project has been funded in whole or in part with federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.